Citron Compares Express Scripts To Philidor: 'Culprit Behind Pharmaceutical Price Gouging'

The culprit behind price gouging?

In tweets sent out Thursday directed at President-elect Donald Trump, Citron Research targeted pharmacy benefit giant Express Scripts Holding Company ESRX, referring to the company as "the Philidor of the pharma industry," and setting a $45 price target for the stock.

Back in October 2015, the short-seller published a "smoking gun" detailing what it calls a "cover up" concerning Valeant's relationship with specialty pharma company Philidor RX.

An Express Scripts spokesperson told Benzinga, "We clearly disagree with [Left's] assertions. We are not at all like Philidor. Express Scripts is a market force that uniquely puts medicine within reach by driving down cost of care and improving health outcomes."

screen_shot_2016-12-08_at_1.15.27_pm.png

screen_shot_2016-12-08_at_1.15.43_pm.png

screen_shot_2016-12-08_at_1.16.11_pm.png

Since the tweets went out, shares of Express Scripts are down over 6 percent at $69.36.

CVS Health Corp CVS also fell, trading recently at $77.97, down 3 percent.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsShort SellersHealth CareMoversGeneralCitron ResearchPhilidor
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!